Vnitr Lek 2016, 62(12):1034-1040

The common position of the Czech professional associations on the consensus of the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine regarding investigation on blood lipids and interpretation of their levels

Vladimír Soška1,2,*, Janka Franeková3, Bedřich Friedecký4,5, Antonín Jabor3, Pavel Kraml6, Hana Rosolová7, Michal Vrablík8
1 Oddělení klinické biochemie; International Clinical Research Center, FN U sv. Anny v Brně
2 II. interní klinika a Katedra laboratorních metod, LF MU, Brno
3 Pracoviště laboratorních metod IKEM a 3. LF UK, Praha
4 SEKK spol. s r.o., Pardubice
5 Ústav klinické biochemie a diagnostiky, LF UK a FN Hradec Králové
6 Centrum pro výzkum diabetu, metabolizmu a výživy, II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha
7 II. interní klinika LF UK a FN Plzeň
8 III. interní klinika 1. LF a VFN v Praze

The aim of this opinion is to summarize and to comment the consensus of the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine, which covers two main areas: 1) whether it is necessary / required to be fasting or non-fasting before blood sampling for lipids measurement, and what are the changes in the concentration of blood lipids during the day; 2) What decision limits (cut off value) of lipids and lipoproteins should be reported from laboratories and what is the recommended procedure for people with extreme / critical blood lipid values. Following parameters are discused: total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, lipoprotein(a). This opinion should be the object of interest both for professionals in clinical laboratories and for physicians in hospitals and out-patients departments.

Keywords: apolipoproteins; blood collection; cholesterol; laboratory testing; lipoprotein(a); cut off limits; triglycerides

Received: November 9, 2016; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V, Franeková J, Friedecký B, Jabor A, Kraml P, Rosolová H, Vrablík M. The common position of the Czech professional associations on the consensus of the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine regarding investigation on blood lipids and interpretation of their levels. Vnitr Lek. 2016;62(12):1034-1040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nordestgaard BG, Langsted A, Mora S et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37(25): 1944-1958. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw152>. Go to original source... Go to PubMed...
    2. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(5): 499-502. Go to original source...
    3. Mora S, Rifai N, Buring JE et al. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009; 55(5): 888-894. Dostupné z DOI: <http://dx.doi.org/10.1373/clinchem.2008.117929>. Go to original source... Go to PubMed...
    4. Tanno K, Okamura T, Ohsawa M et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010; 411: 1774-1780. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2010.07.034>. Go to original source... Go to PubMed...
    5. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>. Go to original source... Go to PubMed...
    6. Soska V, Vaverkova H, Vrablik M et al. [Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011]. Vnitr Lek 2013; 59(2): 120-126. Go to PubMed...
    7. Catapano AL, Graham I, De Backer G et al. ESC/EAS 2016 guidelines for the management of dyslipidemias. Eur Heart J 2016 Aug 27. pii: ehw272. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>. Go to original source... Go to PubMed...
    8. Vaverková H, Soška V, Rosolová H et al. [Czech Atherosclerosis Society Guidelines for the diagnosis and treatment of dyslipidemias in adults]. Vnitr Lek 2007; 53(2): 181-187. Go to PubMed...
    9. Guadagno PA, Summers Bellin EG, Harris WS et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta 2015; 439: 219-224. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2014.10.013>. Go to original source... Go to PubMed...
    10. McConnell JP, Guadagno PA, Dayspring TD et al. Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 2014; 8(6): 550-553. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2014.08.003>. Go to original source... Go to PubMed...
    11. Raal FJ, Giugliano RP, Sabatine MS et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63(13): 1278-1288. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.01.006>. Go to original source... Go to PubMed...
    12. Franeková J, Jabor A, Soška V. Vliv standardní zátěže tukem na koncentrace triacylglycerolů a HDL-cholesterolu. FONS 2016; 26(3): 22-24.
    13. Emerging Risk Factors C, Di Angelantonio E, Sarwar N et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993-2000. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.1619>. Go to original source... Go to PubMed...
    14. Driver SL, Martin SS, Gluckman TJ et al. Fasting or Nonfasting Lipid Measurements: It Depends on the Question. J Am Coll Cardiol 2016; 67(10): 1227-1234. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.12.047>. Go to original source... Go to PubMed...
    15. Soška V, Zima T, Friedecký B et al. Společné doporučení České společnosti klinické biochemie ČLS JEP a České společnosti pro aterosklerózu ČLS JEP ke sjednocení hodnotících mezí krevních lipidů a lipoproteinů pro dospělou populaci. Klin Biochem Metab 2010; 18(1): 45-46.
    16. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118(20): 2047-2056. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.804146>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.